1887

Abstract

Human immunodeficiency virus type 1 (HIV-1) envelope vaccines can now be evaluated for efficacy in macaques by challenging with chimeric viruses in which the and genes of simian immunodeficiency virus (SIV) have been replaced by those of HIV-1. Most experiments have so far been conducted using gp120 molecules derived fromT-cell- adapted LAI or MN strains of HIV-1, which predominantly use the CXCR-4 co-receptor. These vaccines protect against infection by apathogenic chimeric virus carrying the same envelope sequences. In the experiment described here, four macaques were vaccinated with W61D gp120 derived from a low passage Dutch isolate and capable of inhibiting the binding of MIP1 to the co-receptor CCR-5. This vaccine was potent, inducing high titres of binding and neutralizing antibodies against the homologous HIV-1 and tenfold lower titres against a heterologous challenge virus (SHIV) in which the and genes of SIV had been replaced by those of a San Francisco isolate, HIV-1. Despite strong immune responses to the vaccine there was no evidence that it protected against challenge with this chimeric virus. The antigenic divergence between vaccine and challenge virus or the increased virulence of the challenge virus may be responsible for the inability of this vaccine to protect against infection by SHIV.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-79-3-423
1998-03-01
2021-10-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/79/3/9519819.html?itemId=/content/journal/jgv/10.1099/0022-1317-79-3-423&mimeType=html&fmt=ahah

References

  1. Agy M. B., Frumkin L. R., Corey L., Coombs R. W., Wolinsky S. M., Koehler J., Morton W. R., Katze M. G. 1992; nemestrina by human immunodeficiency virus type 1. Science 257:103–106
    [Google Scholar]
  2. Ahmed S., Lohman B., Marthas M., Giavedoni L., El-awad Z., Haigwood N., Scandella C., Gardner M., Luciw P., Yilma T. 1994; Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. AIDS Research and Human Retroviruses 10:195–204
    [Google Scholar]
  3. Berman P. W., Gregory T. J., Riddle L., Nakamura G. R., Champe M. A., Porter J. P., Wurm F. M., Hershberg R. D., Cobb E. K., Eichberg J. W. 1990; Protection of chimpanzee from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345:622–625
    [Google Scholar]
  4. Berman P. W., Murthy K. K., Wrin T., Vennari J. C., Cobb E. K., Eastman D. J., Champe M., Nakamura G. R., Davison D., Powell M. F., Bussiere J., Francis D. P., Matthews T., Gregory T. J., Obijeski J. F. 1996; Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate ofhuman immunodeficiency virus type 1. Journal of Infectious Diseases 173:52–59
    [Google Scholar]
  5. Biti R., French R., Young J., Bennetts B., Steward G. 1997; HIV- 1 infection in an individual homozygous for the CCR5 deletion allele. Nature Medicine 3:252–253
    [Google Scholar]
  6. Bootman J., Kitchin P. 1992; An international collaborative study to assess a set of reference reagents for HIV-1 PCR. Journal of Virological Methods 37:23–42
    [Google Scholar]
  7. Bruck C., Thiriart C., Fabry L., Franchotte M., Pala P., Van Opstal O., Culp J., Rosenberg M., De Wilde M., Heid P., Heeney J. 1994; HIV-1 envelope elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine 12:1141–1148
    [Google Scholar]
  8. Daniel M. D., Letvin N. L., King N. W., Kannagi M., Sehgal P. K., Hunt R. D., Kanki P. J., Essex M., Desrosiers R. G. 1985; Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 228:1201–1204
    [Google Scholar]
  9. Daniel M., Mazzara G., Meredith S., Sehgal P., Kodama T., Panicali D., Desrosiers R. 1994; High titre immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection. AIDS Research and Human Retrovirsuses 10:839–851
    [Google Scholar]
  10. Dunn C. S., Beyer C., Kieny M.-P., Gloeckler L., Schmitt D., Gut J. P., Kim A., Aubertin A.-M. 1996; High viral load and CD4 lymphopaemia in rhesus and cynomolgus macaques infected by a chimeric primate lentivirus constructed using the env, rev, tat and vpu genes from HIV-1 LAI. Virology 223:351–361
    [Google Scholar]
  11. Gardner M. B. 1993; The importance of non human primate research in the battle against AIDS: a historical perspective. Journal of Medical Primatology 22:86–91
    [Google Scholar]
  12. Giavedoni L., Planelles V., Haigwood N., Ahmed S., Kluge J., Marthas M., Gardner M., Luciw P., Yilma T. 1993; Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. Journal of Virology 67:577–583
    [Google Scholar]
  13. Girard M., Kieny M.-P., Pinter A., Barre-Sinoussi F., Nara P., Kolbe H., Kusumi K., Chaput A., Reinhart T., Muchmore E. 1991; Immunization of chimpanzee confers protection against challenge with human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 88:542–546
    [Google Scholar]
  14. Girard M., Meigneir B., Barre-Sinoussi F., Kieny M.-P., Matthews T., Muchmore E., Nara P. L., Wei Q., Rimsky L., Weinhold K. 1995; Vaccine induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. Journal of Virology 69:6239–6248
    [Google Scholar]
  15. Gotch F., Hovell R., Delchambre M., Silvera P., McMichael A. J. 1991; Cytotoxic T-cell response to simian immunodeficiency virus by cynomolgus macaque monkeys immunized with recombinant vaccinia virus. AIDS 5:317–320
    [Google Scholar]
  16. Groenink M., Andeweg A. C., Fouchier R. A. M., Broersen S., van der Jagt R. C. M., Schuitemaker H., de Goede R. E. Y., Bosch M. L., Huisman G. H., Tersmette M. 1992; Phenotype associated env gene variation among eight related human immunodeficiency virus type 1 clones : evidence for in vivo recombination and determinants of cytotropism outside the V3 domain. Journal of Virology 66:6175–6180
    [Google Scholar]
  17. Hedman K., Rousseau S. A. 1989; Measurement of avidity of specific IgG for verification of recent primary rubella. Journal of Medical Virology 27:288–292
    [Google Scholar]
  18. Heeney J. L. 1996; Primate models for AIDS vaccine development. AIDS 10:S115–122
    [Google Scholar]
  19. Hu S.-L., Abrams K., Barber G. N., Moran P., Zarling J. M., Langlois A. J., Kuller L. R., Morton W. R., Benveniste R. E. 1992; Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255:456–459
    [Google Scholar]
  20. Israel Z., Edmonson P., Maul D., O’Neil S., Mossman S., Thiriart C., Fabry L., van Opstal O., Bruck C., Bex F., Burny A., Fultz P., Mullins J., Hoover E. 1994; Incomplete protection, but suppression of virus burden by subunit simian immunodeficiency virus vaccines. Journal of Virology 68:1843–1853
    [Google Scholar]
  21. Katrak K., Mahon B. P., Jones E. C., Brautigam S., Mills K. H. G. 1992; Preparative separation of foreign antigens for highly efficient presentation to T-cells in vitro. Journal of Immunological Methods 156:247–254
    [Google Scholar]
  22. Kent K. A., Kitchin P., Mills K. H. G., Page M., Taffs L. F., Corcoran T., Silvera P., Flanagan B., Powell C., Rose J., Ling C., Aubertin A. M., Stott E. J. 1994; Passive immunization of cynomolgus macaques with immune sera or a pool of neutralizing monoclonal antibodies failed to protected against challenge with SIVmac251. AIDS Research and Human Retroviruses 10:189–194
    [Google Scholar]
  23. Letvin N. L., Montefiori D. C., Yasutomi Y., Perry H. C., Davies H.-E., Lekutis C., Alroy M., Freed D. C., Lord C. I., Handt L. K., Liu M. A., Shiver J. W. 1997; Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proceedings of the National Academy of Sciences, USA 94:9378–9383
    [Google Scholar]
  24. Li J., Lord C. I., Haseltine W., Letvin N. L., Sodroski J. 1992; Infection of cynomolgus macaques with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoprotein. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 5:639–646
    [Google Scholar]
  25. Liu R., Paxton W. A., Choe S., Ceradinia D., Martin S. R., Horuk R., MacDonald M. E., Stuhlmann H., Koup R., Landan N. R. 1996; Homozygous defect in HIV-1 co-receptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 86:367–377
    [Google Scholar]
  26. Lu Y., Salvato M. S., Pauza C. D., Li J., Sodroski J., Manson K., Wyand M., Letvin N., Jenkins S., Tonzian N., Chutkowski C., Kushner N., Lefile M., Payne L. G., Roberts B. 1996; Utility of SHIV for testing HIV-1 vaccine candidates in macaques. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 12:99–106
    [Google Scholar]
  27. Luciw P. A., Pratt-Lowe E., Shaw K. E. S., Levy J. A., Cheng-Mayer C. 1995; Persistent infection of rhesus macaques with T-cell line tropic and macrophage tropic clones of simian/human immunodeficiency viruses (SHIV). Proceedings of the National Academy of Sciences, USA 92:7490–7494
    [Google Scholar]
  28. Mills K. H. G., Page M., Chan W. L., Kitchin P., Stott E. J., Tafs L. F., Jones W., Rose J., Ling C., Silvera P., Corcoran T., Flanagan B., Burny A., Bex F., Delchambre M., Van Opstal O., Fabry L., Thiriart C., Delers A., DeWilde M., Bruck C. 1992; Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant Env and Gag proteins. Journal of Medical Primatology 21:50–58
    [Google Scholar]
  29. Mills K. H. G., Page M., Kitchin P., Chan W. L., Jones W., Silvera P., Corcoran T., Flanagan B., Ling C., Thiriart C., DeWilde M., Bruck C., Rud E., Clarke B., Stott E. J. 1993; Immunization of macaques with SIV env recombinants: specificity of T-cell and antibody responses and evaluation of protective efficacy. Journal of Medical Primatology 22:104–109
    [Google Scholar]
  30. Ranjbar S., Jones S., Stott E. J., Almond N. 1997; The construction and evaluation of SIV/HIV chimeras which express the envelope of European HIV-1 isolates. AIDS Research and Human Retroviruses 12:797–805
    [Google Scholar]
  31. Reimann K. A., Li J. T., Veaze R., Halloran M., Park I. W., Karlsson G. B., Sodroski J., Letvin N. L. 1996; A chimeric simian/human immunodeficiency virus expressing primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. Journal of Virology 70:6922–6928
    [Google Scholar]
  32. Robert-Guroff M., Natuk R. J., Myagkikh M. others 1995; Adenovirus-HIV-lmn env recombinants and a SF2 gp120 boost protect chimpanzees from a SF2 challenge. AIDS Research and Human Retroviruses 11:S136
    [Google Scholar]
  33. Rose J., Silvera P., Flanagan B., Kitchin P., Almond N. 1995; The development of PCR based assays for the detection and differentiation of simian immunodeficiency virus in vivo . Journal of Virological Methods 51:229–240
    [Google Scholar]
  34. Sakuragi S., Shibata R., Mukai R., Komatsu T., Fukasawa M., Saki H., Sakuragi J.-I., Kawamura M., Ibuki K., Hayami M., Adachi A. 1992; Infection of macaque monkeys with a chimeric human and simian immunodeficiency virus. Journal of General Virology 73:2983–2987
    [Google Scholar]
  35. Schultz A. M., Stott E. J. 1994; Primate models for AIDS vaccines. AIDS 8: Suppl. 1 S203–S212
    [Google Scholar]
  36. Shibata R., Kawamura M., Sakai H., Hayami M., Ishimoto A., Adachi A. 1991; Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. Journal of Virology 65:3514–3520
    [Google Scholar]
  37. Silvera P., Flanagan B., Kent K., Rud E., Powell C., Corcoran T., Bruck C., Thiriart C., Haigwood N. L., Stott E. J. 1994; Final analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques. AIDS Research and Human Retroviruses 10:1295–1304
    [Google Scholar]
  38. Stott E. J. 1994; Towards a vaccine against AIDS: lessons from simian immunodeficiency virus vaccines. Current Topics in Microbiology and Immunology 188:221–237
    [Google Scholar]
  39. Stott J., Almond N. 1995; Assessing animal models of AIDS. Nature Medicine 1:295–297
    [Google Scholar]
  40. Stott E. J., Chan W. L., Mills K. H. G., Page M., Taffs L. F., Cranage M., Greenaway P., Kitchin P. A. 1990; Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by whole fixed cell vaccine. Lancet 336:1538–1541
    [Google Scholar]
  41. Trkola A., Dragic T., Arthos J., Binley J., Olson W. C., Allaway G. P., Cheng-Mayer C., Robinson J., Maddon P. J., Moore J. P. 1996; CD4- dependent antibody sensitive interactions between HIV-1 and its co-receptor CCR5. Nature 384:184–187
    [Google Scholar]
  42. Walker M. C., Fast P. 1994; Clinical trials of candidate AIDS vaccines. AIDS 8: Suppl 1 S213–S236
    [Google Scholar]
  43. Warren J. T., Levinson M. A. 1995; Fourth annual survey of worldwide HIV, SIV and SHIV challenge studies in vaccinated nonhuman primates. Journal of Medical Primatology 24:150–168
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-79-3-423
Loading
/content/journal/jgv/10.1099/0022-1317-79-3-423
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error